AU2023901365A0 - Administration of oligonucleotides - Google Patents
Administration of oligonucleotidesInfo
- Publication number
- AU2023901365A0 AU2023901365A0 AU2023901365A AU2023901365A AU2023901365A0 AU 2023901365 A0 AU2023901365 A0 AU 2023901365A0 AU 2023901365 A AU2023901365 A AU 2023901365A AU 2023901365 A AU2023901365 A AU 2023901365A AU 2023901365 A0 AU2023901365 A0 AU 2023901365A0
- Authority
- AU
- Australia
- Prior art keywords
- oligonucleotides
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/AU2023/050961 WO2024229505A1 (en) | 2023-05-05 | 2023-10-05 | Administration of oligonucleotides |
| AU2023447308A AU2023447308A1 (en) | 2023-05-05 | 2023-10-05 | Administration of oligonucleotides |
| PCT/AU2024/050433 WO2024229513A1 (en) | 2023-05-05 | 2024-05-03 | Administration of oligonucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023901365A0 true AU2023901365A0 (en) | 2023-05-18 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4363444A4 (en) | Administration of anti-hpa-1a antibodies | |
| EP4274557A4 (en) | Oral administration of ketamine | |
| EP4190310A4 (en) | Stable pharmaceutical preparation | |
| AU2023901365A0 (en) | Administration of oligonucleotides | |
| EP4114396A4 (en) | Methods of administering elagolix | |
| EP4205765A4 (en) | Stable pharmaceutical preparation | |
| HK40108562A (en) | Oral delivery of oligonucleotides | |
| TWI908143B (en) | Use of ribociclib pharmaceutical compositions for the treatment of cancer | |
| HK40122638A (en) | Combination drug | |
| AU2023902095A0 (en) | Polymer-enabled delivery of pharmaceutical agents | |
| HK40117988A (en) | Lipid-based formulations for administration of rna | |
| HK40110997A (en) | Pharmaceutical compositions of efruxifermin | |
| EP4370117A4 (en) | Pharmaceutical compositions of ozanimod | |
| HK40119846A (en) | Oral dosage forms of elraglusib | |
| HK40113753A (en) | Pharmaceutical formulation | |
| HK40122488A (en) | Pharmaceutical composition comprising centanafadine | |
| HK40117580A (en) | Combination formulation of cedazuridine | |
| AU2024901938A0 (en) | Medicinal Vapes | |
| AU2024901937A0 (en) | Medicinal Vapes | |
| AU2024901936A0 (en) | Medicinal vapes | |
| HK40094133A (en) | Pharmaceutical composition for the treatment of vitiligo | |
| HK40122546A (en) | Combination formulation of cedazuridine | |
| HK40121850A (en) | Pharmaceutical composition | |
| HK40103690A (en) | Novel combined administration | |
| HK40112311A (en) | Pharmaceutical compound |